Inhibition of dihydrofolate reductase: structure-activity correlations of 2,4-diamino-5-benzylpyrimidines based upon molecular shape analysis

Journal of Medicinal Chemistry
1981.0

Abstract

A quantitative structure-activity relationship (QSAR) investigation of a set of 23 substituted 2,4-diamino-5-benzylpyrimidines spanning an activity range of 1.8 log (1/C) units was carried out using molecular shape analysis (MSA). C is the molar concentration necessary for 50% inhibition of bovine liver dihydrofolate reductase (DHFR). The "active" shape of these compounds was deduced by comparing the change in conformational state to the activity of four compounds outside the data base described above. A correlation equation, and analogous in descriptor form to those developed earlier for DHFR inhibition by substituted, 2,4-diaminotriazines and -quinazolines, was constructed. The correlations coefficient, r, was 0.931 and the standard deviation of fit, s, was 0.137. The results suggest that these pyrimidines bind to DHFR with shape features different from both the triazines and quinazolines. It is postulated from the "active" shape of the pyrimidines that it is preferable to substitute at the meta position of the benzyl ring rather than at the para position.

Knowledge Graph

Similar Paper

Inhibition of dihydrofolate reductase: structure-activity correlations of 2,4-diamino-5-benzylpyrimidines based upon molecular shape analysis
Journal of Medicinal Chemistry 1981.0
Quantitative structure-activity relationships for the inhibition of Escherichia coli dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines
Journal of Medicinal Chemistry 1988.0
Theory and application of molecular potential energy fields in molecular shape analysis: a quantitative structure-activity relationship study of 2,4-diamino-5-benzylpyrimidines as dihydrofolate reductase inhibitors
Journal of Medicinal Chemistry 1983.0
Quantitative Structure−Activity Relationships of 2,4-Diamino-5-(2-X-benzyl)pyrimidines versus Bacterial and Avian Dihydrofolate Reductase
Journal of Medicinal Chemistry 1998.0
Inhibition of chicken liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines. A QSAR and graphics analysis
Journal of Medicinal Chemistry 1986.0
Quantitative structure-activity relationship of 5-(X-benzyl)-2,4-diaminopyrimidines inhibiting bovine liver dihydrofolate reductase
Journal of Medicinal Chemistry 1979.0
Comparison of the inhibition of Escherichia coli and Lactobacillus casei dihydrofolate reductase by 2,4-diamino-5-(substituted-benzyl)pyrimidines: quantitative structure-activity relationships, x-ray crystallography, and computer graphics in structure-activity analysis
Journal of Medicinal Chemistry 1982.0
On the structure selectivity problem in drug design. A comparative study of benzylpyrimidine inhibition of vertebrate and bacterial dihydrofolate reductase via molecular graphics and quantitative structure-activity relationships
Journal of Medicinal Chemistry 1989.0
Inhibition of human dihydrofolate reductase by 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-(substituted-phenyl)-s-triazines. A quantitative structure-activity relationship analysis
Journal of Medicinal Chemistry 1984.0
Quantitative structure-selectivity relationships. Comparison of the inhibition of Escherichia coli and bovine liver dihydrofolate reductase by 5-(substituted benzyl)-2,4-diaminopyrimidines
Journal of Medicinal Chemistry 1980.0